SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
4.580
+0.480 (11.71%)
Mar 11, 2026, 4:00 PM EDT - Market closed
SAB Biotherapeutics Market Cap
SAB Biotherapeutics has a market cap or net worth of $233.36 million as of March 11, 2026. Its market cap has increased by 1,387.31% in one year.
Market Cap
233.36M
Enterprise Value
142.71M
1-Year Change
1,387.31%
Ranking
Category
Stock Price
$4.58
Market Cap Chart
Since February 9, 2021, SAB Biotherapeutics's market cap has increased from $130.75M to $233.36M, an increase of 78.47%. That is a compound annual growth rate of 12.07%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 10, 2026 | 208.90M | 17.33% |
| Dec 31, 2025 | 178.05M | 408.46% |
| Dec 31, 2024 | 35.02M | -44.79% |
| Dec 29, 2023 | 63.43M | 113.36% |
| Dec 30, 2022 | 29.73M | -91.24% |
| Dec 31, 2021 | 339.54M | 159.68% |
| Feb 9, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Surrozen | 249.94M |
| Nuvectis Pharma | 244.39M |
| Canton Strategic Holdings | 235.57M |
| Achieve Life Sciences | 232.10M |
| Protalix BioTherapeutics | 232.02M |
| Humacyte | 228.70M |
| Eledon Pharmaceuticals | 224.57M |
| Keros Therapeutics | 223.01M |